Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
What’s that, a win for CD47?
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
